


INFORMATION DISCLOSURE STATEMENT PTO-1449 APR 12 2006 PATENT & TRADEMARK OFFICE		ATTY. DOCKET NO.		SERIAL NO.			
		39749-0001APC		09/403,440			
		APPLICANT: David Philip Lane					
		FILING DATE: 01/19/2000		GROUP: 1642			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
VL	Bottger, A. et al., "Design of a Synthetic Mdm2-Binding Mini Protein that Activates the p53 Response <i>in Vivo</i> ", Current Biology, vol. 7, no. 11, pp. 860-869, 1997.						
EXAMINER	M. T. Davis		DATE CONSIDERED				08/29/08

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 INFORMATION DISCLOSURE STATEMENT	Attorney's Docket No. 39749-0001APC	Application Serial No. 09/403,440
	Applicant(s) David Philip Lane	
(use several sheets if necessary)	Filing Date: January 19, 2000	Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
JL	1.	Nov. 8, 1994	5,362,623	Vogelstein, B., et al.	435/6	435/320	
	2.	May 2, 1995	5,411,860	Vogelstein, B., et al.	435/6	435/91.2	
	3.	May 30, 1995	5,420,263	Burrell, M., et al.	536/23.1	536/23.2	
	4.	May 21, 1996	5,519,118	Vogelstein, B., et al.	530/350	530/388.6	
	5.	Jul. 2, 1996	5,532,348	Huibregtse, J.M., et al.	536/23.5	435/235.1	
	6.	Aug. 27, 1996	5,550,023	Kinzler, K.W., et al.	435/7.1	435/7.2	
	7.	Feb. 25, 1997	5,606,044	Burrell, M., et al.	536/24.31	206/569	
	8.	Apr. 8, 1997	5,618,921	Burrell, M., et al.	530/387.7	530/388.85	
	9.	Dec. 30, 1997	5,702,908	Picksley, S.M., et al.	435/7.8		
	10.	Jun. 23, 1998	5,770,377	Picksley, S.M., et al.	435/7.1	435/7.9	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
							YES	NO
JL	11.	Jan. 6, 1994	WO 94/00601	Levine, A.J., et al., PCT/US93/06063	C12Q 1/68	G01N 33/574		X
	12.	Apr. 14, 1994	WO 94/08241	Zentgraf, H., et al., PCT/EP93/02666	G01N 33/574	C07K 11/00		X
	13.	May 11, 1994	WO 94/10306	Soussi, T., et al., PCT/FR93/01082	C12N 15/12	C07K 7/08		X
	14.	Mar. 23, 1995	WO 95/07934	Tekamp-Olson, P., et al., PCT/US94/10356	C07K 16/28	A61K 39/395		X
	15.	Apr. 2, 1998	WO 98/13064	Lu, X., et al., PCT/GB97/02318	A61K 38/17	38/41		X

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
JL	16.	Ball, K.L., et al., "Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21 ^{WAF1} ", Current Biology, Vol. 7, pp. 71-80, 1996.
	17.	Barak, Y., et al., "mdm2 expression is induced by wild type p53 activity", The EMBO Journal, Vol. 12, pp. 461-468, 1993.
	18.	Barak, Y., et al., "Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest", The EMBO Journal, Vol. 11, pp. 2115-2121, 1992.
	19.	Blommers, M.J.J., et al., "On the Interaction Between p53 and MDM2: Transfer NOE Study of a p53-Derived Peptide Ligated to MDM2", J. Am. Chem. Soc., Vol. 119, pp. 3425-3426, 1997.
	20.	Böttger, A., et al., "Molecular Characterization of the hdm2-p53 Interaction", J. Mol. Biol., Vol. 269, pp. 744-756, 1997.
	21.	Böttger, V., et al., "Comparative study of the p53-mdm2 and p53-MDMX interfaces", Oncogene, Vol. 18, pp. 189-199, 1999.
	22.	Brown, D.R., et al., "The Tumor Suppressor p53 and the Oncoprotein Simian Virus 40 T Antigen Bind to Overlapping Domains on the MDM2 Protein", Molecular and Cellular Biology, Vol. 13, pp. 6849-6857, 1993.

EXAMINER:


M.T. DAVIS

DATE CONSIDERED:

06/29/06


EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).



Form PTO-1449		Attorney's Docket No. 39749-0001APC	Application Serial No. 09/403,440
INFORMATION DISCLOSURE STATEMENT		Applicant(s) David Philip Lane	
(use several sheets if necessary)		Filing Date: January 19, 2000	Group Art Unit: 1642
23.	Cahilly-Snyder, L., et al., "Molecular Analysis and Chromosomal Mapping of Amplified Genes Isolated from a Transformed Mouse 3T3 Cell Line", Somatic Cell and Molecular Genetics, Vol. 13, pp. 235-244, 1987.		
24.	Chen, J., et al., "Mapping of the p53 and mdm-2 Interaction Domains", Molecular and Cellular Biology, Vol. 13, pp. 4107-4114, 1993.		
25.	Chorev, M., et al., "A Dozen Years of Retro-Inverso Peptidomimetics", Acc. Chem. Res., Vol. 26, pp. 266-273, 1993.		
26.	Crystal, R.G., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success", Science, Vol. 270, pp. 404-410, 1995.		
27.	Deffie, A., et al., "The Tumor Suppressor p53 Regulates Its Own Transcription", Molecular and Cellular Biology, Vol. 13, pp. 3415-3423, 1993.		
28.	Derossi, D., et al., "The Third Helix of the Antennapedia Homeodomain Translocates through Biological Membranes", The Journal of Biological Chemistry, Vol. 269, pp. 10444-10450, 1994.		
29.	Dyson, N., et al., "Adenovirus E1A Makes Two Distinct Contacts with the Retinoblastoma Protein", Journal of Virology, Vol. 66, pp. 4606-4611, 1992.		
30.	Dyson, N., et al., "Homologous Sequences in Adenovirus E1A and Human Papillomavirus E7 Proteins Mediate Interaction with the Same Set of Cellular Proteins", Journal of Virology, Vol. 66, pp. 6893-6902, 1992.		
31.	Farmer, G., et al., "Wild-type p53 activates transcription <i>in vitro</i> ", Nature, Vol. 358, pp. 83-86, 1992.		
32.	Funk, W.D., et al., "A Transcriptionally Active DNA-Binding Site for Human p53 Protein Complexes", Molecular and Cellular Biology, Vol. 12, pp. 2866-2871, 1992.		
33.	Gannon, J.V., et al., "Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form", The EMBO Journal, Vol. 9, pp. 1595-1602, 1990.		
34.	García-Echeverría, C., et al., "Structure-Activity Studies of Peptide Inhibitors of the p53-HDM2 Interaction", Oncology Research.		
35.	Kern, S.E., et al., "Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression", Science, Vol. 256, pp. 827-830, 1992.		
36.	Lane, D., "Interruption of binding of MDM-2 and p53 protein; potential for the treatment of cancer", Exp. Opin. Ther. Patents, Vol. 6, pp. 805-809, 1996.		
37.	Lane, D., et al., "On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage", Phil. Trans. R. Soc. Lond., B, Vol. 347, pp. 83-87, 1995.		
38.	Lee, H.S., et al., "Molecular Characterization of <i>nosA</i> , a <i>Pseudomonas stutzeri</i> Gene Encoding an Outer Membrane Protein Required To Make Copper-Containing N ₂ O Reductase", Journal of Bacteriology, Vol. 173, pp. 5406-5413, 1991.		
39.	Lees-Miller, S.P., et al., "Human DNA-Activated Protein Kinase Phosphorylates Serines 15 and 37 in the Amino-Terminal Transactivation Domain of Human p53", Molecular and Cellular Biology, Vol. 12, pp. 5041-5049, 1992.		
40.	Lin, J., et al., "Functions of the p53 Protein in Growth Regulation and Tumor Suppression", Cold Spring Harbor Symposia on Quantitative Biology, Vol. LIX, pp. 215-223, 1994.		
41.	Lin, J., et al., "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein", Genes & Development, Vol. 8, pp. 1235-1246, 1994.		
42.	Lin, Y., et al., "Inhibition of Nuclear Translocation of Transcription Factor NF- κ B by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence", The Journal of Biological Chemistry, Vol. 270, pp. 14255-14258, 1995.		
43.	Liu, X., et al., "The p53 Activation Domain Binds the TATA Box-Binding Polypeptide in Holo-TFIID, and a Neighboring p53 Domain Inhibits Transcription", Molecular and Cellular Biology, Vol. 13, pp. 3291-3300, 1993.		
44.	Martin, K., et al., "Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein", Nature, Vol. 375, pp. 691-698, 1995.		

EXAMINER: M. T. Davis	DATE CONSIDERED: 06/29/06
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2162343 v1	



Form PTO-1449		Attorney's Docket No. 39749-0001APC	Application Serial No. 09/403,440
INFORMATION DISCLOSURE STATEMENT		Applicant(s) David Philip Lane	
(use several sheets if necessary)		Filing Date: January 19, 2000	Group Art Unit: 1642
45.	Michalovitz, D., et al., "Conditional Inhibition of Transformation and of Cell Proliferation by a Temperature-Sensitive Mutant of p53", Cell, Vol. 62, pp. 671-680, 1990.		
46.	Mundt, M., et al., "The tumor suppressor p53 as a target for tumor therapy: An <i>In vitro</i> transcription system as an indicator of active p53".		
47.	Oliner, J.D., et al., "Amplification of a gene encoding a p53-associated protein in human sarcomas", Nature, Vol. 358, pp. 80-83, 1992.		
48.	Olson, D.C., et al., "Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes", Oncogene, Vol. 8, pp. 2353-2360, 1993.		
49.	Orkin, S.H., et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy", pp. 1-23, 1995.		
50.	Otto, A., et al., "Upregulation of mdm-2 Expression in Meth A Tumor Cells Tolerating Wild-type p53", Oncogene, Vol. 8, pp. 2591-2603, 1993.		
51.	Phelan, J.C., et al., "A General Method for Constraining Short Peptides to an α -Helical Conformation", Journal of the American Chemical Society, Vol. 119, pp. 455-460, 1997.		
52.	Picksley, S.M., et al., "The p53-mdm2 Autoregulatory Feedback Loop: A Paradigm for the Regulation of Growth Control by p53?", BioEssays, Vol. 15, pp. 689-690, 1993.		
53.	Picksley, S.M., et al., "p53 and Rb: their cellular roles", Current Opinion in Cell Biology, Vol. 6, pp. 853-858, 1994.		
54.	Rojanasakul, Y., "Antisense oligonucleotide therapeutics: drug delivery and targeting", Advanced Drug Delivery Reviews, Vol. 18, pp. 115-131, 1996.		
55.	Schlaeppli, J.M., et al., "Identification of Specific hdm2 Binding Peptides by Affinity Selection and Mass Spectrometry", Novartis Pharma AG, 1997.		
56.	Schlichtholz, B., et al., "The Immune Response to p53 in Breast Cancer Patients Is Directed against Immunodominant Epitopes Unrelated to the Mutational Hot Spot", Cancer Research, Vol. 52, pp. 6380-6384, 1992.		
57.	Stephen, C.W., et al., "Characterisation of Epitopes on Human p53 using Phage-displayed Peptide Libraries: Insights into Antibody-Peptide Interactions", J. Mol. Biol., Vol. 248, pp. 58-78, 1995.		
58.	Stull, R.A., et al., "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects", Pharmaceutical Research, Vol. 12, pp. 465-482, 1995.		
59.	Unger, T., et al., "p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer", The EMBO Journal, Vol. 11, pp. 1383-1390, 1992.		
60.	Wallace, C., "Peptide ligation and semisynthesis", Current Opinion in Biotechnology, Vol. 6, pp. 403-410, 1995.		
61.	Wasyluk, C., et al., "p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53", Oncogene, Vol. 18, pp. 1921-1934, 1999.		

EXAMINER:	M. T. DAVIS	DATE CONSIDERED:	08/29/06
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).			
SV 2162343 v1			